annb0t
Top 20
MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients. (PRNewsfoto/Tel...
>>> Read more: Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
>>> Read more: Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
